HRAS and oropharyngeal carcinoma: Although no significant differences in OS or PFS were observed between the p16-positive oropharyngeal carcinomas with and without HRAS mutations (Figure 2A,B), the p16-negative oropharyngeal carcinomas with HRAS mutations showed a significantly shorter PFS than those without HRAS mutations (Figure 2C,D).